• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病运动障碍的危险因素分类。

Classifying risk factors for dyskinesia in Parkinson's disease.

机构信息

Consultant Physician and Honorary Professor, Sherwood Forest hospitals NHS Trust, University of Nottingham, UK.

出版信息

Parkinsonism Relat Disord. 2010 Sep;16(8):490-7. doi: 10.1016/j.parkreldis.2010.06.003. Epub 2010 Jul 3.

DOI:10.1016/j.parkreldis.2010.06.003
PMID:20598622
Abstract

BACKGROUND

Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia.

METHODS

We conducted literature search to identify and classifying risk factors into groups - (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable.

RESULTS

Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor.

CONCLUSION

Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia.

摘要

背景

目前尚无适用于个体帕金森病患者发生运动障碍的风险因素分类。

方法

我们进行了文献检索,将风险因素分为两组 - (a) 内在与外在,(b) 可改变与不可改变。

结果

年龄较小、发病年龄较小和帕金森病的严重程度是运动障碍的主要内在不可改变的风险因素,女性是另一个因素,但不是独立于其他因素。遗传表达和可塑性可能决定帕金森病和运动障碍的发病年龄,这些目前是由于内在和外在因素相互作用而产生的不可改变的因素。初始体重较低和疾病过程中的体重减轻会增加运动障碍的风险。每公斤体重的左旋多巴剂量比绝对左旋多巴剂量更重要的风险因素。早期使用长效非左旋多巴(即多巴胺激动剂)药物可延迟运动障碍的发生。体重、左旋多巴剂量以及药物输送的方式和持续时间之间的相互作用是一个重要的可改变因素。

结论

帕金森病中的运动障碍是内在与外在以及可改变与不可改变因素相互作用的结果。确定个体患者的可改变因素并加以处理可能会降低运动障碍的风险和负担。根据疾病过程中的体重调整左旋多巴剂量似乎是运动障碍的一个重要可改变风险因素。

相似文献

1
Classifying risk factors for dyskinesia in Parkinson's disease.帕金森病运动障碍的危险因素分类。
Parkinsonism Relat Disord. 2010 Sep;16(8):490-7. doi: 10.1016/j.parkreldis.2010.06.003. Epub 2010 Jul 3.
2
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.腺苷受体与帕金森病中左旋多巴诱导的运动障碍:一种新治疗方法的潜在靶点
Exp Neurol. 2003 Dec;184(2):556-60. doi: 10.1016/S0014-4886(03)00402-3.
3
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.中国特发性帕金森病患者运动并发症发生的危险因素
J Clin Neurosci. 2009 Aug;16(8):1034-7. doi: 10.1016/j.jocn.2008.10.015. Epub 2009 May 9.
4
Risk and course of motor complications in a population-based incident Parkinson's disease cohort.基于人群的帕金森病发病队列中运动并发症的风险及病程
Parkinsonism Relat Disord. 2016 Jan;22:48-53. doi: 10.1016/j.parkreldis.2015.11.007. Epub 2015 Nov 6.
5
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.帕金森病胎儿黑质移植后运动障碍的临床模式及危险因素:基于视频的双盲分析
Mov Disord. 2009 Feb 15;24(3):336-43. doi: 10.1002/mds.22208.
6
The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.左旋多巴剂量和体重对帕金森病流行人群运动障碍的影响。
Parkinsonism Relat Disord. 2011 Jan;17(1):27-9. doi: 10.1016/j.parkreldis.2010.10.005. Epub 2010 Nov 3.
7
Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.左旋多巴诱发的帕金森病肚皮舞样异动症:一例报告
Mov Disord. 2010 Aug 15;25(11):1760-2. doi: 10.1002/mds.23345.
8
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.异动症可预测帕金森病患者左旋多巴单药治疗中运动反应波动的发生。
Parkinsonism Relat Disord. 2005 May;11(3):151-5. doi: 10.1016/j.parkreldis.2004.10.002.
9
l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.左旋多巴诱导的运动障碍 - 临床特征、遗传学和治疗。
Int Rev Neurobiol. 2011;98:31-54. doi: 10.1016/B978-0-12-381328-2.00002-X.
10
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.司立吉林治疗帕金森病异动症:一项双盲安慰剂对照试验。
Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226.

引用本文的文献

1
Identifying Risk Factors and Constructing Predictive Models for Wearing-Off and Dyskinesia in Chinese Patients With Parkinson's Disease on Long-Term Levodopa Therapy.识别长期接受左旋多巴治疗的中国帕金森病患者剂末现象和异动症的风险因素并构建预测模型
CNS Neurosci Ther. 2025 Aug;31(8):e70544. doi: 10.1111/cns.70544.
2
Sexual Dimorphism in Levodopa-Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory.帕金森病后左旋多巴诱发异动症的性别差异:未知领域
Eur J Neurosci. 2025 May;61(9):e70144. doi: 10.1111/ejn.70144.
3
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
帕金森病中左旋多巴诱发异动症的基因荟萃分析。
NPJ Parkinsons Dis. 2023 Aug 31;9(1):128. doi: 10.1038/s41531-023-00573-2.
4
Identification and quantitative assessment of motor complications in Parkinson's disease using the Parkinson's KinetiGraph™.使用帕金森运动记录仪(Parkinson's KinetiGraph™)对帕金森病运动并发症进行识别和定量评估。
Front Aging Neurosci. 2023 Aug 1;15:1142268. doi: 10.3389/fnagi.2023.1142268. eCollection 2023.
5
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.帕金森病中左旋多巴诱发异动症的基因荟萃分析。
medRxiv. 2023 May 30:2023.05.24.23290362. doi: 10.1101/2023.05.24.23290362.
6
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease.限制还是不限制?优化饮食中蛋白质对帕金森病左旋多巴吸收的相互作用的实际考量。
NPJ Parkinsons Dis. 2023 Jun 24;9(1):98. doi: 10.1038/s41531-023-00541-w.
7
Changes in the Secretion of Melatonin and Selected Adipokines during the Progression of Parkinson's Disease-Preliminary Studies.帕金森病进展过程中褪黑素及某些脂肪因子分泌的变化——初步研究
Metabolites. 2023 May 18;13(5):668. doi: 10.3390/metabo13050668.
8
Bilateral Globus Pallidus Interna Combined With Subthalamic Nucleus Variable Frequency Deep Brain Stimulation in the Treatment of Young-Onset Parkinson's Disease With Refractory Dyskinesia: A Case Report.双侧苍白球内侧部联合丘脑底核变频脑深部电刺激治疗青年型帕金森病伴难治性异动症:一例报告
Front Neurosci. 2021 Nov 25;15:782046. doi: 10.3389/fnins.2021.782046. eCollection 2021.
9
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease.性别相关的早期帕金森病患者运动、非运动和生物学特征的纵向变化。
J Parkinsons Dis. 2022;12(1):421-436. doi: 10.3233/JPD-212892.
10
Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID).左旋多巴诱发异动症(LID)的环路机制
Front Neurosci. 2021 Mar 10;15:614412. doi: 10.3389/fnins.2021.614412. eCollection 2021.